Evolution of HER2-Targeted Therapy in Gastroesophageal Adenocarcinoma

Did you know that HER2-targeted therapy is an established treatment option for patients with HER2-positive metastatic gastric/gastroesophageal junction (GEJ) cancer?

Credit available for this activity expires: 3/29/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1000593?ecd=bdc_podcast_libsyn_mscpedu